Skip to content

Microflare Protocol in Poor Responders

Growth Hormone Co-treatment With the Microflare Stimulation Protocol in IVF/ICSI, Can it be a New Hope for Poor Responders?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02185326
Enrollment
145
Registered
2014-07-09
Start date
2014-07-31
Completion date
2014-12-31
Last updated
2015-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility Due to Diminished Ovarian Reserve

Keywords

Poor responders, Poor ovarian response, IVF/ICSI, Microflare protocol, Growth hormone, Oral contraceptive pills

Brief summary

The effect of use of the microflare down regulation protocol on the outcome of the IVF/ICSI cycles in poor responders

Detailed description

The microflare as a method of down regulation protocol can be used to prepare the females suffering from poor ovarian reserve to undergo IVF/ICSI cycles. In this study we are trying to outline its effect on the clinical pregnancy rate as a main primary outcome, and to compare its use with the addition of growth hormone to the same protocol.

Interventions

Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.

Sponsors

Woman's Health University Hospital, Egypt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* females fulfilling the criteria of the ESHRE consensus 2011: At least two of the following three features must be present: (i) Advanced maternal age (≥40 years) or any other risk factor for POR; (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml).

Exclusion criteria

* women who suffer from any other cause of infertility other than poor ovarian reserve * refusal of the patient to consent for using her data in the study.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rates15 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026